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a b s t r a c t
Neuropathic pain may be caused by a variety of lesions or diseases of both the peripheral and
central nervous system. The most common and best known syndromes of peripheral
neuropathic pain are painful diabetic neuropathy, trigeminal and post-herpetic neuralgia,
persistent post-operative and post-traumatic pain, complex regional pain syndrome, cancer-
related neuropathic pain, HIV-related neuropathic pain and pain after amputation. The less
common central pain comprises primarily central post-stroke pain, pain after spinal cord
injury, central pain in Parkinson disease or in other neurodegenerative diseases, pain in
syringomyelia and in multiple sclerosis.
A multidisciplinary team of Polish experts, commissioned by the Polish Association for
the Study of Pain and the Polish Neurological Society, has reviewed the literature on various
types of neuropathic pain, with special focus on the available international guidelines, and
has formulated recommendations on their diagnosis and treatment, in accordance with the
principles of evidence-based medicine (EBM). High quality studies on the efﬁcacy of various
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medicines and medical procedures in many neuropathic pain syndromes are scarce, which
makes the recommendations less robust.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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1.1. Diagnosis
Post-herpetic neuralgia (PHN) is the unilateral pain located
within dermatomes affected by viral infection, persisting or
recurring more than 3 months after the onset of herpes zoster
infection and after the healing of skin lesions. It occurs in
9–15% of patients who have suffered from herpes zoster
[41,105].
Pain in PHN may be persistent or paroxysmal; it has
burning, stinging, throbbing or sharp and shooting quality,
resembling stabbing or electric shock. Usually, it increases in
the evening and at night. It is exacerbated by cold rainy
weather and stress. Examination reveals sensory abnormali-
ties including allodynia, hyperalgesia and hyperesthesia.
The risk factors for PHN include: age, female sex, severe
pain before the onset of rash, location within the ﬁrst branch
of the trigeminal nerve, involvement of dermatomes not
adjacent to each other, diabetes, history of cancer or other
immune compromising diseases and very severe acute phase
of the disease with intense pain as well as involvement
of multiple dermatomes. Pain may resolve spontaneously
within a few months, but in some patients it persists for years
or even for life [61,105].
1.2. Treatment
Efﬁcacy of a live attenuated virus vaccine (Zostavax) has been
demonstrated for the prevention of zoster and PHN (the
incidence of zoster reduced by 61.1% and the risk of PHN
development reduced by 66.5%) [83]. The use of an antiviral
drug (acyclovir) up to 48 h after the onset of skin lesions limits
the viral proliferation in structures of the nervous system and
reduces the incidence of PHN. The incidence of PHN is also
reduced by effective pain management in the acute phase of
the disease with the use of non-opioid analgesics, weak or
strong opioids, sympathetic nerve blocks, intravenous infu-
sions of lidocaine as well as antidepressants and antic-
onvulsants [12].
Recent systematic review and a meta-analysis of 28 studies
evaluating the efﬁcacy of 20 different drugs in over 4000
patients with PHN concluded that nearly all of these drugs
were superior to placebo; the best evidence on the efﬁcacy was
provided for pregabalin, gabapentin, 8% capsaicin and ami-
triptyline. Of treatment studied in more than 50 patients, the
greatest pain reduction has been achieved with opioids, while
pregabalin at a daily dose of at least 300 mg was the most
effective drug to achieve 30% or 50% reduction in pain [100].
The recommendations for PHN treatment, including those
prepared by the International Association for the Study of Pain(IASP) [38] and the European Federation of Neurological
Societies (EFNS) [5] experts, have been published recently
and were quite consistent. According to them, the drugs with
the level A evidence include: 8% capsaicin, gabapentin,
pregabalin, 5% lidocaine patches, opioids (morphine, oxyco-
done, and methadone) and tricyclic antidepressants (TCAs)
(amitriptyline, desipramine and nortriptyline – the last two
are not available in Poland).
Management of a patient with PHN depends on the type of
pain reported. If allodynia or hyperalgesia predominate topical
treatment is recommended (patches with 5% lidocaine or 8%
capsaicin), as well as inﬁltration anesthesia with 1% lidocaine
and sympathetic nerve blocks in the area of pain. Otherwise,
pregabalin, gabapentin and TCAs are recommended, as they
effectively alleviate spontaneous pain with burning compo-
nents and paresthesias. Opioids are recommended for pain
of high intensity [5,6,38,39,76].
Similarly to the other types of neuropathic pain, manage-
ment should start with monotherapy. Alternative monother-
apy ought to be tried, if the ﬁrst-choice drug fails. If
monotherapy is ineffective, combined pharmacotherapy is
possible (e.g. an anticonvulsant with an antidepressant, 5%
lidocaine with an anticonvulsant and an antidepressant, or 5%
lidocaine with an anticonvulsant, an antidepressant and an
opioid) [23].
Sympathetic nerve blocks are used in some centers despite
the lack of evidence for their efﬁcacy. The efﬁcacy of blocks is
the higher, the earlier it is used, which may result from
inhibition of response resulting from hypersensitivity of
damaged axons or their endings to released noradrenaline
[26,40,111].
Other non-pharmacological methods, such as acupunc-
ture, transcutaneous electrical nerve stimulation (TENS), laser
therapy, topical cooling or spinal cord stimulation, may also be
used in some cases refractory to physical therapy and
pharmacotherapy [4].
1.3. Recommendations
1. PHN may be diagnosed in individuals suffering from
unilateral pain located in dermatomes in which acute
lesions caused by the zoster virus have occurred. PHN may
be diagnosed after the complete healing of these lesions.
2. Among many drugs of proven efﬁcacy, the following are
recommended as a ﬁrst-line therapy: pregabalin, gabapen-
tin, 8% capsaicin, 5% lidocaine patches, amitriptyline and
opioids.
3. The choice of the ﬁrst drug should be based on the intensity
and type of pain as well as comorbidities.
4. If subsequent monotherapies fail, it is possible to use a
combination of drugs from different therapeutic groups.
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2.1. Diagnosis
Complex regional pain syndrome (CRPS) is a particular type of
neuropathic pain affecting distal part of an upper or lower
limb. Two forms of this syndrome have been distinguished:
type I (reﬂex sympathetic dystrophy, RSD) without conﬁrmed
peripheral nerve injury and type II (causalgia) with concomi-
tant peripheral nerve injury. The incidence of CRPS-I is
assessed at 5.5/100,000 and of CRPS-II at 4.5/100,000.
Pathological lesions in CRPS occur at many levels of the
nervous system involved in nociception, and they result in
sensory, motor and autonomic disturbances within a limb
affected by pain. The syndrome is triggered by a noxious
stimulus acting peripherally, often a slight injury or immobi-
lization of peripheral part of a limb. The signs of CRPS are
usually limited to one limb or its part, but they can spread to
other limbs. Usually, pain is accompanied by peripheral
sensory disturbances, mild weakness and other motor
disturbances, as well as swelling, vasomotor dysfunction
and other autonomic lesions. Involuntary movements, such as
tremor or dystonia, are observed in some patients. Patients
suffering from CRPS often experience anxiety, depression,
pain catastrophizing, pain behaviors, focusing on signs, and
fear of the consequences of disease.
The recently published criteria for CRPS diagnosis intro-
duced a list of typical symptoms and signs assigned to four
categories of disturbances: positive sensory, vasomotor,
sudomotor/edema, as well as motor/trophic disturbances.
According to these criteria, CRPS may be diagnosed in clinical
practice based on the presence of at least one symptom in at
least three of the abovementioned categories and at least
one sign in at least two categories [53].
2.2. Treatment
Due to the complex nature of its occurrence, CRPS is very
difﬁcult to treat. None of the medicines or non-pharmacologi-
cal methods of treatment achieved level A evidence. So far,
only lamotrigine, TCA and opioids have been shown to be
effective in single randomized or other large case-series
(grade B). In practice, various methods of physical therapy,
psychotherapy, local anesthesia techniques, neuromodula-
tion and pharmacotherapy are used in the treatment of this
syndrome. Comprehensive rehabilitation is the basis for
therapy, and multidirectional, integrated treatment is aimed
at the restoration of limb function. The choice of intervention
in a given case depends on the type and severity of symptoms.
Vitamin C at a dose of 500 mg/day may be effective in the
prophylaxis of CRPS, as documented by a study among
patients after wrist fracture [115].
Physical therapy should be initiated as soon as possible.
Intensity of procedures should be tailored individually to the
limit of pain. Procedures perceived as painful may cause
deterioration. There are no studies that might help to identify
which method of physical therapy would be the most effective
for a given patient [71,75]. Occupational therapy aimed at the
improvement of limb functioning is especially recommended
in the case of CRPS with symptoms in the upper limb [81].Psychotherapy is recommended in the cases where
psychological or psychiatric examination reveals mental
disorders which may be responsible for the occurrence or
persistence of pain. However, there is no evidence conﬁrming
the efﬁcacy of different forms of psychotherapy [13,30,54,71].
The use of analgesics according to the WHO scheme is
recommended; there are no controlled trials to support that
notion, however. This applies to non-steroidal anti-inﬂam-
matory drugs (NSAIDs), paracetamol, as well as weak and
strong opioids. Non-steroidal anti-inﬂammatory drugs or
paracetamol may be given to patients with pain of low or
moderate intensity. Tramadol, being effective in many other
neuropathic pain syndromes, may also be used in CRPS.
Despite the fact that there is no evidence on efﬁcacy, many
experts consider opioids to be one of the basic elements of
multidirectional treatment of severe CRPS not responding to
other forms of treatment [54,56]. Prednisolone 30–40 mg/d was
given orally in the acute phase of CRPS, decreasing the
intensity of disease symptoms. However, there are no
controlled trials concerning the use of steroids in CRPS [13].
Ligands of a2d subunit of the calcium channel, i.e.
pregabalin and gabapentin, may be given, especially if the
pain is paroxysmal in nature. Treatment should be discon-
tinued if there is no effect after 8 weeks. The therapeutic effect
after administration of pregabalin occurs earlier than after
gabapentin. Tricyclic antidepressants, such as amitriptyline,
may be effective in CRPS despite the lack of randomized
studies, especially if a patient has continuously persisting
symptoms. Ketamine at sub-anesthetic doses administered
intravenously in an inpatient may be an alternative treatment
for patients who are treatment-resistant or suffer from
exacerbation [102]. Sodium channel blockers (lidocaine and
mexiletine) reduced pain intensity in small groups of patients
(intravenous infusion of lidocaine), or in individual cases
only (mexiletine). Mexiletine is not currently available in
Poland due to serious side effects. Topical capsaicin is not
recommended in CRPS [86].
Other medications may be used in particular situations.
Antispastic drugs (baclofen, diazepam or clonazepam) may be
effective in patients with spasticity or dystonia. Intrathecal
baclofen should be considered only in the case of spasticity
resistant to other forms of treatment [13]. Medicines regulating
calcium levels, such as calcitonin and bisphosphonates, may
or even should be used if there is a conﬁrmed increase of bone
metabolism [73]. In this indication, slow intravenous infusion
of pamidronate (60 mg/day within 4 h used for 3 subsequent
days) or neridronate (100 mg within 2 h given 4 times for 10
days) has shown some beneﬁcial effects. Dimethyl sulfoxide
in the form of a 50% cream can be used if CRPS lasts longer than
a year. Another free radical scavenger, N-acetylcysteine at a
dose of 600 mg three times daily, may be used for three months
in patients with decreased skin temperature [13,72,86]. There
are also some single reports on the efﬁcacy of calcium
antagonists (nifedipine and nitrendipine), which can be used
at appropriate doses for a week, and then only in patients
whose response to the therapy is positive [13,72].
If there is evidence that pain is supported by the
sympathetic nervous system, e.g. reduction in pain and
improvement of blood supply to the limb after sympathetic
nerve blocks with a local anesthetic, sympathetic ganglion
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considered instead of the previously used surgical sympath-
ectomy [7,22]. Spinal cord stimulation in selected cases is cost-
effective as an adjuvant to the standard pharmacological
therapy, but some complications that required additional
procedures can be expected in up to 25% of patients [65].
2.3. Recommendations
1. CRPS should be diagnosed according to the diagnostic
criteria by a physician experienced in diagnosing pain
syndromes.
2. Data from previous trials evaluating the efﬁcacy of various
medicines do not allow formulating clear recommenda-
tions on a sequence of their use.
3. If opioids and other medicines recommended in neuro-
pathic pain fail or in some particular cases and in speciﬁc
indications, one may reach for other interventions, such as
antispastic drugs or bisphosphonates, and even invasive
therapies, such as sympathetic blocks.
4. In the opinion of experts, any treatment is more effective if
it is multidirectional, and if it is initiated early.
5. The most important element of multidirectional treatment
is active physical therapy, which should not be perceived by
a patient as painful.
6. Psychological therapy may be effective if psychological
factors are involved in the mechanism of pain, or if a patient
hopes for it.
3. Painful diabetic polyneuropathy
3.1. Diagnosis
Both type 1 (insulin deﬁciency) and type 2 (resistance to insulin)
diabetes mellitus are the most common causes of peripheral
polyneuropathy in adults. At the moment of type 2 diabetes
diagnosis, 8% of patients already present with signs of
neuropathy [84]. Diabetes-induced damage to the nerves can
affect each type of nerve ﬁbers (sensory, motor and autonomic),
both thick myelinated and thin unmyelinated ﬁbers. Apart from
damage to the axon (axonal neuropathy), damage to the myelin
(demyelinating neuropathy) is found as well. The nerve ﬁbers
that are damaged the most often are those in peripheral nerves,
plexuses (plexopathy) and radices (diabetic polyradiculoneuro-
pathy), and less commonly in cranial nerves, e.g. oculomotor
nerves. Because of the complexity of possible damage, clinical
picture of diabetic neuropathy can be divergent (mononeuro-
pathies, multiple mononeuropathies, or polyneuropathies).
Diabetic neuropathy-associated pain can be nociceptive
(when the tissues are damaged) or neuropathic (when there is
damage to the nervous system). Both types of pain coexist in
many cases. Development of diabetic neuropathy and associ-
ated neuropathic pain depends on several different mecha-
nisms [116].
Chronic distal symmetric sensorimotor polyneuropathy,
which presents with pain in approximately 20–30% of patients,
is the most common type of painful diabetic neuropathy.
Acute painful sensory polyneuropathy and asymmetric
polyradiculoneuropathy occur signiﬁcantly less often. Painfulcompression neuropathies, e.g. carpal tunnel syndrome, are
more common among diabetics than in general population.
The clinical picture of diabetic polyneuropathy does not
differ from polyneuropathies associated with other diseases.
The process of diabetic polyneuropathy is individual and
difﬁcult to predict. Polyneuropathy can develop unnoticeably
to patients, and even doctors, for many months or even years.
Typically, it starts with mild and gradually progressing
superﬁcial and deep sensation disturbances, which are later
joined by pain, distal muscle weakness, diminished or absent
deep tendon reﬂexes, muscle atrophy and trophic skin lesions.
Signs are usually symmetric; initially, they affect feet and then
gradually move in the proximal direction. At the same time or
slightly later, the same signs are observed in the upper limbs.
Signs and symptoms resulting from damage to thick nerve
ﬁbers include impaired position and vibration sense, slower
nerve conduction and the decreased deep tendon reﬂexes.
Damage to thin ﬁbers leads to pain and impaired temperature
perception. Some patients experience dysesthesia, which is
deﬁned as unpleasant and painful sensation of tingling,
numbness or any other sensation occurring spontaneously
or induced by different stimuli and typical for neuropathic
pain.
The diagnosis of diabetic neuropathy can be made on the
basis of patient's medical history and results of neurological
examination, after excluding other possible causes of neurop-
athy. In the case of damage to thick nerve ﬁbers, a diagnosis
can be conﬁrmed by neurophysiological examination. It is
recommended to measure the conduction velocity in sensory
and motor nerve ﬁbers and determine the response amplitude
and terminal latency [31,36]. In order to diagnose thin
nerve ﬁber neuropathy, special examination techniques must
be employed, e.g. skin biopsy or quantitative sudomotor axon
reﬂex test [85].
3.2. Treatment
Diabetic neuropathy treatment, especially in advanced cases,
is difﬁcult and often ineffective. Complete elimination of
pain or the reduction in its intensity by half is achieved only in
half of the patients. That is why the following prophylactic
measures play a special role: diagnosis of diabetes and its
metabolic control, adherence to a proper diet, treatment with
insulin or oral medicines in order to keep a glucose level within
normal limits on a permanent basis and proper lifestyle. Strict
glycaemic control, taking aldose reductase inhibitors or
immunoglobulins slow down the disease progression [104].
Infections, exposure to toxic substances and limb injuries
should be avoided. Smoking and alcohol use are discouraged
as well.
In recent years, a number of recommendations regarding
treatment of painful diabetic polyneuropathy have been
published by American Diabetes Association [17], EFNS [5],
American Academy of Neurology (AAN) [19] and multispecialty
group of European and American experts (The Toronto Consensus
Panel on Diabetic Neuropathy) [103], among others. All these
publications recommend TCAs, calcium channel a-2-dligands
and serotonin-norepinephrine reuptake inhibitors (SNRIs) as a
ﬁrst-line treatment. The next choices are tramadol, alone or
together with acetaminophen, or strong opioids. Treatment
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from one of the three above-mentioned therapeutic groups on
the basis of coexisting diseases and contraindications. If the
treatment is unsuccessful or adverse effects make it necessary
to discontinue the treatment, it is recommended to switch to
another ﬁrst-line medicine. If a ﬁrst-line treatment fails, it is
recommended to start a combination treatment consisting of
medicines from different therapeutic groups, both ﬁrst-line and
next-line choice. AAN and Toronto panel experts clearly point
out pregabalin and duloxetine as medicines having the best-
documented efﬁcacy in their therapeutic groups.
TCAs, particularly amitriptyline, have had a well-estab-
lished role among medicines recommended in the treatment
of painful diabetic neuropathy for many years. Because of good
therapeutic indices in neuropathic pain treatment (number
needed to treat [NNT]: 2.1; 95% CI: 1.8–3.9), efﬁcacy similar to
other medicines, e.g. duloxetine [63] and pregabalin [8], and
low price, many experts consider TCAs as a ﬁrst-line treatment
in diabetic neuropathy. Due to possible severe adverse effects
associated with this treatment, the administration of amitrip-
tyline has some limitations. The treatment starts with a dose
of 10–25 mg, which is gradually increased up to 50–150 mg/day.
Serum level of amitriptyline does not correlate with its
analgesic action. Beneﬁcial effects of amitriptyline in neuro-
pathic pain are revealed very quickly, as soon as after the ﬁrst
week of treatment. Lack of efﬁcacy and switch to a new
medicine should not be considered before three to four weeks
of taking a constant dose of the medicine.
Evidence on the efﬁcacy of ﬁrst-generation anticonvulsants
(carbamazepine and phenytoin) comes from studies per-
formed many years ago; their methodology does not meet
current requirements. However, many Polish experts believe
that these drugs serve well in practice and recommend their
use; this applies especially to carbamazepine [29,32].
Evidence on the efﬁcacy of calcium channel a-2-d ligands,
gabapentin and pregabalin derives from many randomized
clinical trials [47,85,92,94]. NNT for gabapentin at a dose of 900–
3600 mg/day is 6.4 (95% CI: 4.3–12), while for pregabalin at a
dose of 300–600 mg/day it amounts to 4.7 (95% CI: 4.0–5.6) [85].
Standard simple analgesics and NSAIDS, due to lack of clear
efﬁcacy in the treatment of neuropathic pain, are not
recommended. Tramadol administered orally at a dose of
200 mg/day has clear evidence of efﬁcacy in diabetic neuropa-
thy pain. Strong opioids are particularly recommended in
patients with signiﬁcant pain intensity and resistance to
previously taken medicines.
Lidocaine administered intravenously at a dose of 3–5 mg/
kg of body weight for 30 min is another medicine that has been
used for many years in the treatment of painful diabetic
neuropathy. Its analgesic effect is quite short-lasting, which is
why it should be administered several times per day. NNT for
lidocaine in this indication is 2.5 [85]. Signiﬁcantly worse
effects were observed with mexiletine (NNT: 10), which is
currently not recommended due to its adverse effects.
Despite not being approved, 8% capsaicin and 5% lidocaine
patches can also be used in some cases. NNT for capsaicin in the
treatment of diabetic neuropathy is within the range of 2.5–4.9,
while for lidocaine within 2.2–5.9. Open-label pilot study showed
that a three-week long treatment with 5% lidocaine patch
signiﬁcantly reduced pain and improved the quality of life [9].Acupuncture can have a certain signiﬁcance as an adjuvant
treatment. Treatment consisting of six cycles of traditional
Chinese acupuncture, administered during a period of 10
weeks, brought considerable pain relief in 77% of patients [2].
3.3. Recommendations
1. Patients diagnosed with diabetes should maintain an
appropriate blood glucose level as a prophylactic measure.
2. First-line treatment of painful diabetic neuropathy
includes: TCAs, pregabalin and gabapentin, as well as
duloxetine and venlafaxine ER.
3. Second-line medicines in the treatment of painful diabetic
neuropathy are: tramadol and strong opioids.
4. Treatment should be commenced with one medicine
chosen with regard to individual contraindications and
coexisting diseases. If the ﬁrst-line monotherapy is ineffec-
tive or if adverse effects occurred, it is recommended to
switch to alternative medication from a different therapeu-
tic group.
5. In case of lack of efﬁcacy, it is recommended to switch to a
medicine with a different mechanism of action; change to
a second-line medicine (ideally one with a different
mechanism of action); or add another ﬁrst- or second-line
medicine (observing the principles of rational pharmaco-
therapy).
4. Trigeminal neuralgia
4.1. Diagnosis
Trigeminal neuralgia (TN) (neuralgia trigemini, tic douloureux) is
the most common type of face neuralgia. Its prevalence is
about 3–6 cases per 100,000 people and increases with age [69].
The pain is most commonly located in the area of the second
and third branch of the trigeminal nerve, less often it affects all
three branches and in very rare cases it is limited to the ﬁrst
branch only [114]. A characteristic feature of TN is the
existence of trigger zones or trigger points, i.e. points or areas
which induce paroxysmal pain even with a gentle touch. Most
commonly, a few or a dozen of paroxysmal pain attacks can
occur within 24 h, yet their frequency can increase with time,
thus causing the patient to experience constant pain.
Typically, the disease has a relapsing-remitting course, with
relapses lasting from a few weeks to several months or even
years. Remissions can last for months or even years. However,
the periods of remission gradually become shorter, whereas
pain attacks increase their intensity and length up to a few
hours per day. The character of pain can also evolve from
sharp to dull and deep. Pain is usually located on one side, but
may affect the other side with another relapse [89]. In-between
the attacks, there are no neurological signs or symptoms
within the previously painful region.
4.2. Treatment
Clinical guidelines on NT management were published in 2008
by the joint team of AAN and EFNS experts [27,50]. According to
these recommendations, the ﬁrst-line drugs for NT are
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those drugs, the surgery is indicated. However, grade A
recommendation is only for carbamazepine. The studies on
oxcarbazepine support recommendation at grade B. Carba-
mazepine should be administered in gradually increasing
divided doses, ranging from 100 to 1200 mg/day. In Poland,
oxcarbazepine is not registered as a treatment for TN. Other
drugs, like lamotrigine, clonazepam or baclofen (grade C
recommendation) can be considered as options for patients
who have not responded to carbamazepine.
The efﬁcacy of classic analgesics such as most commonly
used NSAIDs is relatively low, similarly to TCAs, which can be
used for treating concomitant depression. In case of poor
response to pharmacotherapy, botulin toxin therapy can be
considered before surgery [28].
The most commonly used invasive methods of TN therapy
include Gasserian ganglion thermolesion or surgical proce-
dures: microvascular decompression of the nerve root or
stereotactic radiosurgical procedures [68].
4.3. Recommendations
1. Diagnosis of TN can be made based on the occurrence of
paroxysmal pain located solely in the region of the
trigeminal nerve innervation.
2. Carbamazepine is a ﬁrst-line treatment for TN.
3. In case of carbamazepine intolerance or known contra-
indications for its use, other antiepileptic drugs can be
administered (lamotrigine, gabapentin, and pregabalin), as
well as baclofen and clonazepam.
4. Interventional procedures should be considered in case of
ineffective pharmacotherapy.
5. The therapy with botulin toxin can be considered before
surgery.
5. Post-amputation pain
5.1. Diagnosis
Phantom pain experienced in an amputated extremity and
stump pain located around the post-surgical scar on the
stump, are two out of three basic pain disorders following
amputation, apart from non-painful sensation localized in the
phantom extremity or illusions that the missing limb is still
present [57]. Frequency of the phantom pain following an
amputation of an extremity varies and ranges from 4 up to
88%. It depends e.g. on the pain intensity level assumed as the
limit to diagnose the case as phantom pain and the time which
has passed since the procedure.
5.2. Treatment
Treatment of post-amputation pain comprises not only
pharmacotherapy but also psychotherapy, non-invasive elec-
trostimulation, other physical methods, as well as invasive
procedures.
The efﬁcacy of many drugs recommended for the man-
agement of neuropathic pain is controversial in the case ofpost-amputation pain. As an example, amitriptyline (up
to 125 mg/day) was ineffective in the treatment of post-
amputation pain in a study by Robinson et al. [93], whereas
other study published one year later did prove the efﬁcacy of
amitriptyline at dose of 75 mg/day [110]. Similarly, gabapen-
tin reduced the intensity of phantom pain when administered
at a dose of 2400 mg/day in the study of Bone et al. [15], while
according to Smith et al. [98], it was not effective at a dose of
3600 mg/day.
Morphine was effective in some studies in decreasing the
level of phantom limb pain and stump pain (NNT: 2–4.5), but
the analgesic effect proved only a 30% reduction of pain
[58,112].
Other drugs used for alleviating the pain caused by
amputation include: ketamine administered intravenously,
which decreases phantom pain and hyperalgesia [79], dextro-
methorphan, which decreased phantom pain by 50% in 50% of
patients [1], lidocaine which alleviated the stump pain but not
phantom pain at a dose of 4 mg/kg administered in an
intravenous infusion [113], and calcitonin, which decreased
the intensity of the phantom pain when administered
intravenously in an early post-operational phase [42].
Cochrane library analysis published in 2011 focused on six
therapeutic groups (NMDA antagonists, antidepressants,
antiepileptic drugs, anesthetics, opioids and calcitonin)
showed only modest efﬁcacy of morphine, gabapentine and
ketamine. Memantine and amitriptyline were ineffective in
this analysis [3].
Low effectiveness of pharmacotherapy results in other
treatment methods being applied, especially physiotherapy
and psychotherapy. The outcomes of research assessing
the effectiveness of electrostimulation and acupuncture are
ambiguous. Massage and passive movements may prevent
trophic and vascular changes around the stump. Despite the
lack of evidence for its effectiveness, another psychothera-
peutic method commonly used in phantom pain is hypnosis.
Furthermore, certain studies prove a decrease in phantom
limb pain following special visual training (mirror box therapy)
[67,80].
Block of a peripheral nervous system and neurodestruction
can also be useful in patients with stump pain. If the source
of pain is a neuroma, thermolesion can be performed,
following a positive outcome of a diagnostic and prognostic
nerve block [67,80]. In selected cases of phantom limb pain,
thermolesion of the spinal cord or neurostimulation within
peripheral nerves, spinal cord or deep brain stimulation can
prove effective [78].
5.3. Recommendations
1. Despite the lack of clear evidence for the efﬁcacy of
pharmacotherapy in stump pain and phantom limb pain
treatment, the following medications are recommended:
amitriptyline, gabapentin, pregabalin, tramadol, strong
opioids, calcitonin and lidocaine infusions.
2. In stump pain, also physical therapy, peripheral nerve block
and neurodestruction can be applied, whereas for phantom
pain methods such as thermolesion of the spinal cord,
peripheral nerve and spinal cord stimulation as well as deep
brain stimulation are available.
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post-amputation pain, such as acupuncture, hypnosis or
neuromodulation (TENS), has not been conﬁrmed in clinical
trials in a way which would allow their recommendation.
6. Persistent post-operative and post-
traumatic pain
6.1. Diagnosis
Persistent post-operative pain (PPP) or persistent post-trau-
matic pain (PTP) is deﬁned as chronic, pathological pain, which
is associated with surgery or trauma and is present for more
than normal tissue healing time, and its intensity, character
and localization cannot be explained by the occurrence of
other pathologies, such as disease recurrence, infection or
cancer recurrence. PPP is most often the result of intraoper-
ative or post-traumatic damage to the structures of the
peripheral nervous system and that is why it usually has
the character of neuropathic pain. Persistent post-operative
pain develops most often after surgical procedures within the
trunk (20–50% after breast surgery, 30–50% after thoracotomy)
or extremities (up to 70% after extremity amputation) [87].
The frequency of the persistent post-operative pain
occurrence is highly dependent on the extent and invasive-
ness of the employed surgical procedure. Application of
minimally invasive and nerve-sparing techniques signiﬁcant-
ly decreases the risk of generation of persistent post-operative
pain [64]. Important risk factors for persistent post-operative
pain development are also insufﬁciently treated acute post-
operative pain of high intensity, young age, long-lasting
surgical procedure and genetic predisposition.
6.2. Treatment
There is evidence that a proper analgesic procedure, when
analgesics are administered at an early stage of surgery, can
signiﬁcantly reduce the frequency of persistent post-operative
pain. It has been documented inter alia that:
 Epidural analgesia administered before thoracotomy and
continued during the intraoperative and post-operative
period signiﬁcantly reduces the frequency of persistent
post-operative pain (recommendation class II) [95].
 Continuous epidural analgesia in patients undergoing colon
resection procedure decreases the frequency of persistent
post-operative pain (recommendation class II) [70].
 Post-surgical wound inﬁltration with local anesthetic
decreases the number of patients with persistent post-
operative pain after brain tumor resection (recommendation
class II) [10].
 Perispinal nerve block before, during and after the mastec-
tomy procedure reduces the frequency of persistent post-
operative pain in such patients (recommendation class II)
[62].
 Administration of gabapentin or mexiletine in the perioper-
ative period reduces the frequency of neuropathic pain after
the mastectomy procedure (recommendation class II) [46]. Administration of intravenous lidocaine infusions at a
dose of 2–3 mg/kg of body weight for 7–10 days after the
surgery in patients from the risk groups reduces the
frequency of persistent post-operative pain occurrence
and intensity [49].
 If persistent post-operative pain occurs, causative man-
agement, e.g. decompression or fusion of the damaged
nerve, should be performed whenever it is possible. Other
patients should be treated symptomatically. Since in most
cases persistent post-operative pain is of neuropathic
character, the therapy should be conducted in accordance
with the principles of neuropathic pain treatment. In the
case of localized pain, it is advisable to administer 5%
lidocaine patch in monotherapy or together with systemic
medicines. Appropriate pharmacotherapy should be com-
bined with psychotherapy and proper rehabilitation. In the
treatment of speciﬁc PPP syndromes not responding to
pharmacotherapy, interventional methods of pain relief
are encompassed [40].
6.3. Recommendations
1. In order to reduce the risk of persistent post-operative pain
development, it is advisable to apply:
a regional anesthesia techniques: inﬁltration of post-
surgical wound with local anesthetic; perispinal nerve
block in breast surgery; continuous epidural anesthesia in
thoracic and abdominal surgeries;
b gabapentin or pregabalin during the perioperative period.
2. Although there is no evidence according to EBM criteria
(poorly reliable data), it is advisable to use intravenous
lidocaine infusions in patients from the risk groups.
3. Although there is no evidence according to EBM criteria
(poorly reliable data), persistent post-operative pain should
be treated with:
a Implementation of causative procedures, e.g. decompres-
sion or fusion of the damaged nerve, if it is possible.
b Compliance with neuropathic pain treatment recom-
mendations.
c In the case of localized pain, administering 5% lidocaine
patch in monotherapy or together with systemic med-
icines.
4. In the treatment of speciﬁc PPP syndromes not responding
to pharmacotherapy, interventional methods of pain relief
should be considered.
7. Neuropathic pain in cancer patients
7.1. Diagnosis
Pain in cancer patients may have different origins. The
mechanism of this pain is very often complex, both nocicep-
tive and neuropathic. It is estimated that at least 15–20% of
cancer patients experience neuropathic pain at different
stages of the disease. In the advanced stage of the disease,
this proportion increases up to 1/3 of patients.
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a. cancer through the compression or inﬁltration of the
central or peripheral [48,60] nervous system or associated
with paraneoplastic syndrome [14];
b. anticancer therapy in the form of persistent post-operative
pain caused by intraoperative damage to nervous system
structures (most often in patients after thoracotomy,
mastectomy and amputation [108]) or as neuropathic pain
syndromes caused by radiotherapy (nervous tissue necrosis
or a lesion of plexuses [34]) and chemotherapy [45];
c. diseases related to a cancer, for example post-herpetic
neuralgia; acute varicella zoster virus infection can be
observed in 1–2% of patients suffering from a cancer; as a
consequence, post-herpetic neuralgia develops in 25–50% of
people infected by this virus [37];
d. other diseases not related to cancer, e.g. painful diabetic
polyneuropathy.
Neuropathic pain associated with anticancer therapy most
often has the form of peripheral polyneuropathy and is
observed in 3–7% of patients receiving monotherapy and in up
to 38% of patients taking multidrug chemotherapy [59].
Peripheral polyneuropathy develops most often after taking
platinum derivatives (cisplatin, carboplatin and oxaliplatin),
vinca alkaloids (vincristine), paclitaxel and bortezomib. It
should be noted that chemotherapy-induced polyneuropathy
(CPIN) is the most common neurological adverse effect of
anticancer therapy. Each of the medicines taken in cancer
chemotherapy, through different mechanisms, can cause
damage to sensory nerves. The development of neuropathy
involves gradual increase of symptoms, which are exacerbat-
ing along with the duration of chemotherapy. The symptoms
of neuropathy have a severe, negative impact on the patients'
quality of life. They are one of the most common causes of
reducing the dose or replacing a particular chemotherapy agent.
7.2. Treatment
There are no studies which would allow to formulate recom-
mendations on the highest level of evidence (A). In practice,
opioids are the ﬁrst-line treatment of neuropathic pain in cancer
patients. This is, among others, due to the fact that neuropathic
pain syndromes in this group of patients are the most
common cause of pain of considerable intensity (6–10 points
in the 11-point numeric scale), which is the indication to take
strong opioids. Strong opioids preferred in the neuropathic pain
therapy include buprenorphine (because of its anti-hyperalgesic
effect), oxycodone (because of the fact that, apart from
stimulating m receptors, it is also the agonist of the k opioid
receptor) and methadone (because it blocks NMDA receptors and
affects norepinephrine and serotonin levels). Taking methadone
may result in several drug interactions and is associated
with variable, unpredictable pharmacokinetics. Because of
these reasons, it is most often considered as an opioid taken
after unsuccessful therapy with other opioids [21,44]. In the
treatment of neuropathic pain of moderate intensity (4–6 points
in the 11-point numeric scale) tramadol is recommended [55].
In order to induce more effective analgesia, it is recom-
mended to take an opioid together with gabapentin orpregabalin [23]. It was also proved that pregabalin, as
compared to amitriptyline and gabapentin, signiﬁcantly
reduces the demand for morphine in cancer patients [77],
guarantees more satisfaction from treatment and causes less
adverse events as compared to gabapentin [91].
In the treatment of pain in patients suffering from CPIN, a
signiﬁcant reduction of pain intensity was observed after
therapy with duloxetine [99]. Similarly, venlafaxine proved to
be effective in the prophylaxis and relief of acute neurotoxic
symptoms caused by oxaliplatin – the pain was completely
eased in 31.3% of patients [35].
Interventional (neurodestructive) techniques can be ap-
plied in selected pain syndromes in cancer patients.
7.3. Recommendations
1. In the case of neuropathic pain of moderate intensity, it is
advisable to start the analgesic treatment with tramadol,
whereas in the case of severe pain it is recommended to
start the therapy with a strong opioid.
2. By adding pregabalin or gabapentin, the therapy can be
more effective and the dose of opioids can be reduced.
3. In the treatment of pain associated with post-chemothera-
py painful polyneuropathy, it is recommended to take
duloxetine or venlafaxine.
8. Painful neuropathies in HIV infection
8.1. Diagnosis
Painful sensory polyneuropathy (PSN) is the most common
neurological complication of HIV infection [109]. Two most
frequent PSN forms in HIV infection (PSN-HIV) are distal
sensory polyneuropathy (DSP) and antiretroviral toxic neu-
ropathy (ATN). DSP is caused by the virus, while ATN is the
effect of the treatment of HIV infection. Although the
mechanisms of nerves damage are completely different,
the clinical picture of DSP and ATN is similar. The most
common factors increasing the risk of DSP are: elder age and
disease progression indices such as high viral load and low
CD4 cells count [25].
8.2. Treatment
Most of the controlled studies assessing the efﬁcacy of
different medicines in PSN-HIV have been conducted on small
groups (less than 50 patients). Level A evidence has been
provided only for 8% capsaicin patch [20]. Single publications
described signiﬁcant alleviation of pain in PSN-HIV after
treatment with lamotrigine [96] and gabapentin [52]. Treat-
ment with gabapentin reduced not only the pain (by 44%), but
also improved the comfort of sleep (by 49%). Five-percent
lidocaine [43], pregabalin [97] as well as amitriptyline [74] did
not produce clinically signiﬁcant pain relief in patients
diagnosed with PSN-HIV.
Hypnosis assessed in an uncontrolled study reduced the
pain intensity by 44% in patients with PSN-HIV. Pain relief was
observed over the period of 7 weeks [33].
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 8 ( 2 0 1 4 ) 4 2 3 – 4 3 5 4318.3. Recommendations
1. Eight-percent capsaicin patch is recommended in the
treatment of PSN-HIV, together with gabapentin and
lamotrigine (despite their low level of evidence).
2. Due to the negative results of previous studies, it is not
recommended to take amitriptyline, pregabalin or 5%
lidocaine patches.
9. Central pain
9.1. Diagnosis
According to the ﬁrst deﬁnition of central pain, published by
IASP in 1986, it is ‘‘a pain that accompanies a central nervous
system lesion’’ [101]. At present, in the most common opinion
of experts, central pain is a central type of neuropathic pain
deﬁned as ‘‘a pain caused by a direct lesion or disease of the
central somatosensory nervous system’’ [107].
Contemporary epidemiological data show that pain, espe-
cially chronic one, is a frequent symptom of primary CNS
diseases, and is present in 20–40% of patients; however, in
some diseases, e.g. Parkinson disease, the pain is present even
in 40–60% of patients [16], but only partially it is a pain of
central origin. Because of the predominant contribution of
central pain mechanisms to the generation of pain and, ﬁrst
of all, persistence of pain, some researchers believe that a
number of common pain syndromes treated so far as
peripheral, such as ﬁbromyalgia, irritable bowel syndrome
or tension-type headache, should be regarded and treated as
central pain syndromes [88]. However, there is no direct
evidence that would allow to link these syndromes to a
primary dysfunction or lesion of the central nervous system.
The pathomechanism of central pain is complex. A number
of mechanisms have been documented: e.g. disorganization of
cell-to-cell signaling resulting from nervous system lesions,
hypofunction of GABAergic inhibitory system or microglial
activation [51,106]. Speciﬁc mechanisms are responsible for
the occurrence of pain in different nervous system diseases,
such as multiple sclerosis (MS), central post-stroke pain or
Parkinson disease. These mechanisms are: trigeminal neural-
gia and dysesthesias in MS, spino-thalamic tracts dysfunc-
tions in a stroke, and dystonia and hypokinesia in Parkinson
disease.
Usually, the onset of central pain occurs after a delay of
weeks or months since the ﬁrst symptoms of the acute phase
of the disease have appeared, e.g. stroke or injury, or after
several years of chronic disease, e.g. Parkinson disease.
Originally, the pain is mild or incontinuous, but it increases
gradually over the next weeks and months. The pain is often
experienced as sharp, pricking and shooting, and quite often
as hot and burning. It is accompanied by painful paresthesias
(dysesthesias). Usually, there is no spontaneous remission, the
pain is continuous and is often present for life.
The risk of central pain occurrence does not correlate with
the area and location of the lesion, however, in some
syndromes, such as syringomyelia, the pain is more likely
to occur when the spinal lesion is more extensive.Central post-stroke pain (CPSP) is the better described pain
resulting from a lesion in the central nervous system. It is one
of many possible chronic post-stroke pains, next to shoulder
pain, painful spasticity and tension-type headache. It is
estimated that different forms of chronic post-stroke pain
are present in 11–55% of patients, while CPSP, according to
different statistical data, is present in 1–12% of post-stroke
patients [66].
Central pain in Parkinson disease is associated with the
involvement of the dopaminergic system in the generation of
chronic pain. In Parkinson disease, people complain of pain
signiﬁcantly more frequently than the general population at
the same age and more often than in other neurodegenerative
diseases, such as Alzheimer disease [11]. Pain in Parkinson
disease can have a direct connection with the disease (e.g.
higher pain intensity in ‘‘off’’ states than in ‘‘on’’ states,
dystonic pain) or can be caused by secondary disorders, for
example musculoskeletal pain as a consequence of increased
tension and posture disorders, or radicular pain.
There is an evidence that basal ganglia are involved in
many aspects of pain processing, both in its sensory-
discriminative dimension, and in the emotional-affective
and cognitive aspect, as well as in pain modulation processes.
This is also conﬁrmed by the studies on functional neuroim-
aging in humans. Basal ganglia are activated both in acute
and chronic pain, and this activity is modulated by the
administration of analgesics. Studies performed on human
and animal models showed that the threshold of pain in
Parkinson disease is decreased and administration of levodo-
pa increases it signiﬁcantly [18].
Central pain occurs particularly often in post-traumatic
spinal cord injury, and is then called spinal cord injury pain.
Pain as a result of spinal cord injury is present in 60–70% of
patients, and 30% of patients describe its intensity as very high
and lasting more than a year. In these cases, pain may be
caused by mechanical instability of the spinal cord (resulting
in its displacement and compression by bone structures),
muscle spasm, but also pressure applied to the nerve root and
other pathologies leading to neuropathic pain, such as cauda
equina injury, syringomyelia or segmental deafferentation
pain. Distinction between spinal cord injury pain and the
other abovementioned neuropathic pains based on a clinical
picture is not possible, except for pain in a speciﬁc location
(in the nerve roots or segments of the spinal cord).
Pain in MS, though not so common as in the post-traumatic
spinal cord injury or in Parkinson disease, is the cause of
suffering and deterioration in the quality of life in a signiﬁcant
number of patients. Different forms of chronic pain in MS
are diagnosed in more than 20% of patients, most often in
people over the age of 60 and after several years since the onset
of the disease [82]. Patients particularly often experience
painful burning dysesthesias and other forms of acute pain,
such as trigeminal neuralgia and painful muscle spasms. A lot
of patients suffer from the combination of different pain
syndromes, e.g. dysesthesias, headaches and musculoskeletal
pains, particularly in the sacral area. For therapeutic purposes,
the pain in patients with MS can be categorized into
neuropathic pain directly associated with the disease, pain
indirectly associated with the disease, pain resulting from
therapy and pain not associated with MS [90].
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Recommendations oriented particularly at central pain
(central neuropathic pain) were formulated by a couple of
expert groups, e.g. EFNS [5] and IASP Neuropathic Pain
Special Interest Group – NeuPSIG [38]. The most recent
publications of these groups were issued in 2010 and are
very similar to each other. According to EFNS experts, the
ﬁrst-line treatment in the therapy of central pain includes:
pregabalin (level A), gabapentin (level B, but A in other
neuropathic pains) and amitriptyline (level B, but A in
other neuropathic pains). As a second-line treatment, they
have chosen tramadol (level B). Strong opioids (level B)
were recommended as second-line and third-line treatment
only when there is no need for long-term therapy.
Lamotrigine can be taken in CPSP or in spinal cord injury
pain if the spinal cord damage is incomplete or in the case of
allodynia to touch stimuli (level B). Cannabinoids can be
taken to relieve pain in patients with MS if other forms of
treatment fail (level A). Medications such as valproic acid or
mexiletine were regarded as ineffective in central pain
treatment [5].
In 2012, a group of experts from South Africa issued their
recommendation, in which they proposed pregabalin and
amitriptyline as ﬁrst-line treatment, indicating pregabalin as
preferable because of its documented efﬁcacy, small number
of contraindications and better efﬁcacy-to-risk ratio. Ami-
triptyline or other TCAs, taking contraindications into
account, can be a ﬁrst choice treatment in people with
depression, anxiety and insomnia. After a 2–4 week assess-
ment period, in case of lack of response or bad tolerance,
pregabalin should be changed to amitriptyline, or inversely.
Further lack of response is an indication for the next option –
tramadol – and then a strong opioid [24]. Few results of
randomized clinical trials, which have been published over
the last couple of years, do not change the abovementioned
recommendations.
9.3. Recommendations
1. While diagnosing central pain, one needs to prove its direct
association with a lesion or disease of the central nervous
system. When possible, the etiology of central pain should
be indicated, e.g. central post-stroke pain.
2. Pregabalin is the ﬁrst-line treatment in the therapy of
central pain. In people suffering from depression, anxiety
and insomnia, taking into account contraindications,
amitriptyline or another product from the TCAs group
can be a ﬁrst choice treatment.
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